Meeting Highlights from 16th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

November 29-December 1, 2018
Hilton Universal City Hotel Los Angeles, CA

This three-day multidisciplinary continuing education program brings together internationally recognized specialists to share advances in our understanding of diabetes, cardiometabolic disorders, obesity, cancers involving the endocrine system, endocrine disruptors, and other endocrine conditions, addressing energy balance, bone metabolism, cardiovascular disease, neuroendocrinology, and nutrition to provide a collaborate experience to attendees.

The overarching goal of the Congress is to provide a comprehensive presentation of basic and clinical research as it relates to evolving strategies in patient management and to advance endocrine-related disease management by fostering interactive exchanges. Presentation abstracts are published in the Endocrine Practice.

The theme of 2018 World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIR)—Exploring new frontiers in metabolism: Tomorrow's clinical science today and is sponsored by the Metabolic Institute of America located in Tarzana, California, and chaired by Yehuda Handelsman. 

EndocrineWeb identified four sessions to highlight for those unable to attend:

Are You Proactive in Addressing Signs of Diabetes In Your Patients? It's time to acknowledge that watchful waiting is failing too many of our patientsW. Timothy Garvey, MD, Butterworth Professor of Nutritional Sciences and director of the UAB Diabetes Research Center at the University of Alabama at Birmingham, makes a strong case for clinicians to more actively employ the available tools—anti-diabetes medications that improve glycemic control and reduce cardiovascular risk, anti-obesity medications to promote sufficient weight loss to lessen cardiometabolic risks and onset of type 2 diabetes, and bariatric surgery for the most at-risk patients.1

Matching the right therapy to your patients may be facilitated with the Cardiometabolic Disease Staging System, an algorithm devised by Dr. Garvey and Dr. Guo that reflects risks of cardiovascular, metabolic and obesity rather than just body mass index in evaluating which medications and other therapeutic modalities to address clinical parameters in patients in order  to slow or better yet reverse T2D onset.

Practical Methods of Reducing Atherosclerotic Cardiovascular Diseases. The focus on reducing systemic inflammatory disease remains intriguing as a good therapeutic target for a variety of chronic diseases. Brendan Everett, MD, MPH, assistant professor of medicine at Harvard Medical School and director of the cardiology at Brigham and Women's Hospital, in Boston, Massachusetts, reviewed therapeutic modalities with a particular focus on the beneficial effects of statins, canakinumab, and methotrexate, in conferring a reduction in CVD risk.2

In particular, study findings from both the CANTOS and CIRT trials are reviewed to inform current management of cardiovascular disease risk.

Beyond Baseline Diabetes Management, Metformin May Have a Role in Healthy Aging.  While the complications of diabetes are vast, given the aging population, one of the most worrisome concerns for many patients is cognitive decline. Derek LeRoith, MD, PhD, professor of medicine and director of research in the division of endocrinology at Mount Sinai Hospital and Icahn School of Medicine in New York City discussed the physiological changes of aging that may predispose medical challenges, which increase the risk of type 2 diabetes in many patients in later years.3

While diet is known to have a sizable role in healthy aging, one driver of neuropathology that has garnered particular attention is the formation of advanced glycation end products (AGEs) and its toxic potential not only in diabetes risk but specifically in cognitive decline.

Personalized Care Directed by Gut Microbiome. The role of gut microbiota has been an area of growing attention, according to Eran Segal, PhD, professor of computer science and applied mathematics at the Weizmann Institute of Science, Rehovot, Israel, who introduced compelling evidence in support of environmental differences more so than genetics as the basis for shaping the effects of the gut microbiome on health.4

In fact, distinctive individual intestinal bacteria appear to explain differences in interindividual glucose responses, which led the Segal researcher team to use individual gut microbiota in developing a model for personalizing a diet to achieve more effective blood glucose control.

Last updated on
First Article From This Meeting:
Anti-Inflammatory Therapy for CVD, Diabetes Risk Reduction
close X
SHOW MAIN MENU
SHOW SUB MENU